Dr. Tycel Phillips discusses the implications of the FDA approval of Calquence plus bendamustine and Rituxan in previously untreated mantle cell lymphoma.
In this video, Jennifer A. Woyach, MD, discusses results from the AMPLIFY trial, presented at ASH Annual Meeting and Exhibition.The trial evaluated fixed-duration acalabrutinib (Calquence, AstraZeneca ...
Sumitomo Mitsui Trust Group Inc. grew its stake in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 0.7% during the 4th quarter, according to its most recent 13F filing with the Securities & ...
AstraZeneca has a 52-week low of $61.77 and ... The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta ...
AstraZeneca and Eli Lilly have joined the ... AZ meanwhile is planning to start a trial of its BTK inhibitor Calquence (acalabrutinib), which is currently used to treat various types of blood ...
AstraZeneca’s fast-growing BTK inhibitor Calquence is already challenging class leader Imbruvica from Johnson & Johnson/AbbVie in the treatment of chronic lymphocytic leukaemia (CLL).
Calquence (Acalabrutinib): Acerta Pharma/AstraZeneca Calquence (acalbrutinib) is a Bruton’s tyrosine kinase (BTK) inhibitor used in the treatment of Small Lymphocytic Lymphoma (SLL). It is effective ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...